ADAP Crisis Task Force announces continued partnership with Bristol-Myers Squibb and Boehringer Ingelheim for AIDS Drug Assistance Programs in the United States

0 Comments | Posted

October 28, 2013, Washington, DC – The ADAP Crisis Task Force (Task Force) announced today that it has reached agreement with Bristol-Myers Squibb (BMS) and Boehringer Ingelheim (BI) to extend voluntary discounts/rebates and price freezes to all state AIDS Drug Assistance Programs (ADAPs). The continuation of existing agreements beyond 2013 will provide stability to ADAPs as they continue to navigate the uncharted terrain of a reformed health system as a result of implementation of the Affordable Care Act (ACA) and continued fiscal challenges at both the state and federal level.

The Task Force, convened by the National Alliance of State and Territorial AIDS Directors (NASTAD), previously secured continuation through 2014 of existing agreements for voluntary discounts and rebates from AbbVie, Gilead Sciences, Janssen Therapeutics, Merck and ViiV Healthcare. Many of these agreements also provide continued price freezes for ADAPs for varying lengths of time into 2014 and 2015.

“We applaud BMS and BI for joining other companies in their ongoing commitment to assist ADAPs in providing life-saving medications to people living with HIV who have no other options to obtain coverage for those medications,” stated Chris Hanson, a member of the Task Force and manager of the Michigan ADAP. “Given declining federal and state funding in an era of fiscal austerity as well as uncertainty due to new interactions with the healthcare system, the continued discounts and price freezes are critical for the fiscal stability of ADAPs,” Hanson added.

Julie Scofield, Executive Director of NASTAD, commented that, “With ACA enrollment underway and an uncertain ADAP funding outlook for FY2014, we are very pleased that BMS and BI have agreed to extensions of agreements which will ensure stability for ADAPs through 2014 and beyond. As ADAPs navigate the new health care system and work to implement the ACA, our industry partnerships that extend existing pricing agreements will help continue to ensure access to HIV medications for all those in need,” Scofield concluded.

ADAPs continue to evolve and adapt to health care system changes as the ACA’s public and private insurance expansions are being implemented. The stability of ADAPs is critical as they navigate the unknowns of ACA implementation, including state Medicaid expansion decisions, specifics of drug coverage in Medicaid and the Marketplace insurance plans, and an uncertain timeline for client transition. In addition to the many changes brought about by ACA’s implementation, ADAPs face an uncertain fiscal situation for their FY2014 funding which begins on April 1, 2014. Stability in drug pricing during this period of transition is essential for ADAPs and the people living with HIV whom they serve.


Leave a Comment